menu
    • menu
    [{"orgOrder":0,"company":"Aurigene Oncology","sponsor":"ICMR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aurigene Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aurigene Oncology \/ ICMR","highestDevelopmentStatusID":"12","companyTruncated":"Aurigene Oncology \/ ICMR"},{"orgOrder":0,"company":"Aurigene Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ribrecabtagene Autoleucel","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aurigene Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aurigene Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurigene Oncology \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Aurigene Oncology

    Menu

    Aurigene Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aurigene Oncology

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aurigene Oncology

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribrecabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurigene Reports Positive Outcomes from CAR-T Cell Therapy Phase 1 Trial

                            Details : DRL-1801 (ribrecabtagene autoleucel) is a novel autologous BCMA directed CAR-T cell therapy. It is being evaluated in patients for the treatment of relapsed/refractory multiple myeloma.

                            Brand Name : DRL-1801

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 08, 2024

                            Lead Product(s) : Ribrecabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aurigene Oncology

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aurigene Oncology

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : ICMR

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ICMR partners with industry leaders for groundbreaking First-in-Human Phase-1 cl ..

                            Details : Under the partnership, ICMR will engage in collaborative research on a small molecule for multiple myeloma with Aurigene oncology.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : ICMR

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth